MedTrace Logo

Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.

NCT03542058 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-05-31

No results posted yet for this study

Summary

The objective of this research is to describe the burden of subclinical anthracycline therapy related cardiac dysfunction( ATRCD) by applying international guideline on Uganda cancer patient and to evaluate the significance of treating subclinical ATRCD with carvedilol.

Conditions

  • Chemotherapy Related Cardiac Dysfunction

Interventions

DRUG

Carvedilol

Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.

Sponsors & Collaborators

  • University of Cape Town

    collaborator OTHER

  • Uganda Cancer Institute

    collaborator OTHER

  • Makerere University

    lead OTHER

Principal Investigators

  • Karen Sliwa, PhD · Hatter Institute for Cardiovascular Disease in Africa

  • Feriel Azibani, PhD · Hatter Institute for Cardiovascular Disease in Africa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-30
Primary Completion
2021-06-30
Completion
2021-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542058 on ClinicalTrials.gov